SCHEMBL16521093

SCHEMBL16521093

CCOC(=O)c1c(N)sc2c(OCc3ccccc3)c(Br)ccc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.78
▸ MEN1 O00255 7/20 0.78
▸ KMT2A Q03164 7/20 0.78
▸ NPSR1 Q6W5P4 2/20 0.78
▸ ALOX15 P16050 2/20 0.72
▸ USP2 O75604 1/20 0.72
▸ GAA P10253 4/20 0.64
▸ TSHR P16473 2/20 0.64
▸ MAPK1 P28482 1/20 0.49
▸ ALDH1A1 P00352 6/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ GRM6 O15303 4/20 0.46
▸ HPGD P15428 3/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ POLB P06746 2/20 0.45
▸ NTSR1 P30989 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ MITF O75030 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15184999 0.81 MAPT (0.78) MAPTMEN1KMT2ANPSR1ALOX15
SCHEMBL31460309 0.78 MAPT (1.00) MAPTMEN1KMT2ANPSR1ALOX15
SCHEMBL3990578 0.75 MAPT (0.64) MAPTMEN1KMT2ANPSR1ALOX15
SCHEMBL1590178 0.74 KMT2A (0.52) MAPTMEN1KMT2AUSP2GAA
SCHEMBL5918920 0.73 PRKCZ (0.56) MAPTMEN1KMT2AALOX15USP2
SCHEMBL1590281 0.72 ALDH1A1 (0.50) MAPTMEN1KMT2AUSP2GAA
SCHEMBL1590733 0.71 KMT2A (0.50) MAPTMEN1KMT2AALOX15USP2
SCHEMBL31643757 0.71 KMT2A (0.48) MAPTMEN1KMT2AUSP2GAA
SCHEMBL1534048 0.71 NPC1 (0.50) MAPTKMT2AGAAMAPK1ALDH1A1
SCHEMBL1591418 0.71 KMT2A (0.47) MAPTMEN1KMT2AUSP2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150056141-A1 BENZOTHIOPHENE COMPOUND, ALTERNATIVE AUTOPHAGY-INDUCING AGENT AND ANTICANCER AGENT INCLUDING THE COMPOUND AS ACTIVE INGREDIENT, AND METHOD FOR SCREENING FOR COMPOUND HAVING ANTICANCER ACTIVITY NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) 2015-02-26 — — US disclosed
US-20150056141-A1 BENZOTHIOPHENE COMPOUND, ALTERNATIVE AUTOPHAGY-INDUCING AGENT AND ANTICANCER AGENT INCLUDING THE COMPOUND AS ACTIVE INGREDIENT, AND METHOD FOR SCREENING FOR COMPOUND HAVING ANTICANCER ACTIVITY NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) 2015-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150056141-A1 BENZOTHIOPHENE COMPOUND, ALTERNATIVE AUTOPHAGY-INDUCING AGENT AND ANTICANCER AGENT INCLUDING THE COMPOUND AS ACTIVE INGREDIENT, AND METHOD FOR SCREENING FOR COMPOUND HAVING ANTICANCER ACTIVITY TFEB, SQSTM1, ATG7 MAPT 236/4885MEN1 3584/4885KMT2A 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback